Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 6 515-521, Copyright © 1998 by American Association for Cancer Research

ARTICLES

K-ras mutation in focal proliferative lesions of human pancreas

PG Terhune, DM Phifer, TD Tosteson and DS Longnecker
Department of Pathology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA.

The K-ras gene is mutated in > or =75% of human pancreatic adenocarcinomas and in a number of hyperplastic ductal lesions from noncarcinoma patients. In this study, the incidence of K-ras mutation was determined in a spectrum of focal proliferative pancreatic lesions to evaluate their preneoplastic significance. PCR-based mutation-enriched RFLP analysis was used to identify mutations in codon 12. Immunostaining for Ki67 and p53 was also performed. Forty-seven % of intraductal nonpapillary hyperplasias (8 of 17) contained codon 12 mutations, as did 55% of adenomatoid hyperplasias (6 of 11). This rate increased to 61% in papillary hyperplasias (27 of 44) and to 78% when there was severe dysplasia (7 of 9). The fraction of cells staining for the Ki67 proliferation marker showed a general correlation with the rate of K-ras mutation. Nuclear staining for p53 protein was seen only in two ductal lesions with severe dysplasia. No mutations were found in normal acinar tissue (n = 38), squamous metaplasia (n = 13), ductal complexes (n = 8), or focal acinar cell dysplasia (n = 5). There seemed to be a general correlation of proliferative potential with the presence of K-ras mutation in ductal lesions. However, because of the high prevalence of lesions with K-ras mutations, we conclude that this mutation alone cannot be taken as proof of significant risk for progression to carcinoma. Efforts to use the presence of K-ras mutations in DNA harvested from pancreatic juice or duodenal aspirates as an approach for diagnosis of occult pancreatic carcinoma seem vulnerable to a high false-positive rate.

This article has been cited by other articles:

				P Maisonneuve, A B Lowenfels, B Mullhaupt, G Cavallini, P G Lankisch, J R Andersen, E P DiMagno, A Andren-Sandberg, L Domellof, L Frulloni, et al. Cigarette smoking accelerates progression of alcoholic chronic pancreatitis Gut, April 1, 2005; 54(4): 510 - 514. [Abstract] [Full Text] [PDF]

				S. E. Dowen, T. Crnogorac-Jurcevic, R. Gangeswaran, M. Hansen, J. J. Eloranta, V. Bhakta, T. A. Brentnall, J. Luttges, G. Kloppel, and N. R. Lemoine Expression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer Am. J. Pathol., January 1, 2005; 166(1): 81 - 92. [Abstract] [Full Text] [PDF]

				J. Gotoh, M. Obata, M. Yoshie, S. Kasai, and K. Ogawa Cyclin D1 over-expression correlates with {beta}-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3{beta} and ERK1/2 in mouse hepatic carcinogenesis Carcinogenesis, March 1, 2003; 24(3): 435 - 442. [Abstract] [Full Text] [PDF]

				A. V. Biankin, J. G. Kench, A. L. Morey, C.-S. Lee, S. A. Biankin, D. R. Head, T. B. Hugh, S. M. Henshall, and R. L. Sutherland Overexpression of p21WAF1/CIP1 is an Early Event in the Development of Pancreatic Intraepithelial Neoplasia Cancer Res., December 1, 2001; 61(24): 8830 - 8837. [Abstract] [Full Text] [PDF]

				R. H. Hruban, M. Goggins, J. Parsons, and S. E. Kern Progression Model for Pancreatic Cancer Clin. Cancer Res., August 1, 2000; 6(8): 2969 - 2972. [Full Text]

				G. D. Sorenson Detection of Mutated KRAS2 Sequences as Tumor Markers in Plasma/Serum of Patients with Gastrointestinal Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2129 - 2137. [Abstract] [Full Text]

				R. E. Wilentz, C. A. Iacobuzio-Donahue, P. Argani, D. M. McCarthy, J. L. Parsons, C. J. Yeo, S. E. Kern, and R. H. Hruban Loss of Expression of Dpc4 in Pancreatic Intraepithelial Neoplasia: Evidence That DPC4 Inactivation Occurs Late in Neoplastic Progression Cancer Res., April 1, 2000; 60(7): 2002 - 2006. [Abstract] [Full Text]